Upsher-Smith launches new website for Qudexy XR

MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Monday announced the launch of its enhanced website for Qudexy XR (topiramate) extended-release capsules.

The site features Upsher-Smith’s Access Pathways Program designed to reduce the barriers associated with prescribing the medication and offers healthcare professionals the tools they need to help patients start Qudexy XR therapy, the company said. These tools include an informational video, a guide on how to get started and a patient enrollment form. In addition to being indicated to treat certain types of seizures, Qudexy XR is now indicated for use in the prevention of migraine headache in adults and adolescents 12 years of age or older.

“Upsher-Smith understands that access and affordability for extended-release brand products can be a challenge for patients and an administrative hurdle for physician offices,” said Rusty Field, president and CEO, Upsher-Smith. “The updated website offers resources that will allow them to prescribe Qudexy XR with greater ease.”

Eligible patients enrolled in the Access Pathways Program will receive a $0 co-pay offer. Patients paying cash or those who many not have insurance will benefit from a low-cost option, according to the company. The program also offers:

• 
  Benefit verification


• 
  Prior authorization support


• 
  E-voucher pharmacy finder


• 
  Pharmacy stocking assistance

Click here for more information on Qudexy XR.